Fig. 1 · Structure

Documents & Downloads

Grazoprevir

Cat. No. A17303 CAS 1350514-68-9

Hepatitis C virus NS3/4a protease inhibitor

Grazoprevir (MK-5172) is a selective inhibitor of Hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants, with Kis of 0.01 nM (gt1b), 0.01 nM (gt1a), 0.08 nM (gt2a), 0.15 nM (gt2b), 0.90 nM (gt3a), respectively.

In Stock

Publications for Grazoprevir

2 publications citing this product

  1. Deqiang Kong, .et al. , Nat Commun, 2024, Jun 8;15(1):4894 PMID: 38849338
  2. Xinyi Wang, .et al. , Nat Chem Biol, 2023, Oct 23 PMID: 37872400

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Grazoprevir (MK-5172) inhibits HCV NS3/4A protease. The tested baseline genotype enzymes showed subnanomolar Ki values, while A156T and A156V variants were less sensitive. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Cellular Effect

Cell Line Activity Value Description Reference
Huh-7 EC50 0.2 nM Antiviral activity against HCV genotype 1b infected in human Huh7 cells incubated for 96 hrs by luciferase assay [PMID: 34405680]
Huh-7 EC50 0.3 nM Antiviral activity against HCV genotype 1a infected in human HuH7 cells assessed as inhibition of viral replication after 72 hrs by RT-PCR method [PMID: 26819676]
Huh-7 EC50 0.3 nM Antiviral activity against HCV genotype 1b infected in human HuH7 cells assessed as inhibition of viral replication after 72 hrs by RT-PCR method [PMID: 26819676]
Huh-7 EC50 0.6 nM Antiviral activity against HCV genotype 1a infected in human HuH7 cells assessed as reduction viral RNA level after 72 hrs by RT-PCR method [PMID: 27994759]
Huh-7 EC50 0.6 nM Antiviral activity against HCV genotype 1b infected in human HuH7 cells assessed as reduction viral RNA level after 72 hrs by RT-PCR method [PMID: 27994759]
Huh-7 EC50 1.2 nM Antiviral activity against HCV genotype 2a infected in human HuH7 cells assessed as inhibition of viral replication after 72 hrs by RT-PCR method [PMID: 26819676]
Huh-7 EC50 1.5 nM Antiviral activity against Hepatitis C virus genotype 1b infected in HuH7 cells assessed as reduction in replicon RNA level after 72 hrs by TaqMan-based RT-PCR analysis in presence of 10% FBS [PMID: 24900818]
Huh-7 EC50 12 nM Antiviral activity against HCV genotype 1b harboring D168A mutant infected in human Huh7 cells incubated for 96 hrs by luciferase assay [PMID: 34405680]
Huh-7 EC50 13 nM Antiviral activity against Hepatitis C virus genotype 3a infected in HuH7 cells assessed as reduction in replicon RNA level after 72 hrs by TaqMan-based RT-PCR analysis in presence of 10% FBS [PMID: 24900818]
Huh-7 EC50 261 nM Antiviral activity against HCV genotype 1b harboring A156T mutant infected in human Huh7 cells incubated for 96 hrs by luciferase assay [PMID: 34405680]
Huh-7 EC50 5 nM Antiviral activity against HCV genotype 2b infected in human HuH7 cells assessed as inhibition of viral replication after 72 hrs by RT-PCR method [PMID: 26819676]
Huh-7 EC50 5.4 nM Antiviral activity against HCV genotype 2a infected in human HuH7 cells assessed as reduction viral RNA level after 72 hrs by RT-PCR method [PMID: 27994759]
Huh-7 IC50 7 nM Antiviral activity against Hepatitis C virus genotype 1a infected in human HuH7 cells assessed as inhibition of viral replication after 24 hrs presence of 40% NHS [PMID: 24900473]
Huh-7 EC50 7.2 nM Antiviral activity against HCV genotype 3a infected in human HuH7 cells assessed as reduction viral RNA level after 72 hrs by RT-PCR method [PMID: 27994759]
Huh-7 EC50 7.2 nM Antiviral activity against HCV genotype 3a infected in human HuH7 cells assessed as inhibition of viral replication after 72 hrs by RT-PCR method [PMID: 26819676]
Huh-7 IC50 7.4 nM Antiviral activity against Hepatitis C virus (isolate Con1) genotype 1b infected in human HuH7 cells assessed as inhibition of viral replication after 24 hrs in presence of 50% NHS [PMID: 24900473]

16 records · Scroll to view more

Grazoprevir Research Summary

This section summarizes 3 in vitro studies and 1 in vivo study of Grazoprevir from 3 published references.

Grazoprevir In Vitro Studies

MK-5172 reduced HCV RNA in stable replicon assays. Potency varied with genotype, serum condition and variant; the A156T result and the serum-associated EC50 shift limit broad potency generalizations. [1]

In engineered mammalian cells, grazoprevir selectively redirected NS3a toward the GNCR1 reader at the plasma membrane. This chemical-control application required introduced fusion proteins. [2]

NS3/4A protease inhibition across the tested enzyme panel

Biochemical assay · Recombinant HCV NS3/4A proteases from genotypes 1a, 1b, 2a, 2b and 3a, with separately assayed genotype 1b variants. [1]

MK-5172 inhibited the tested baseline enzymes at subnanomolar Ki values. Activity was weaker against A156T and A156V. Vaniprevir, danoprevir and TMC435 were parallel reference inhibitors in Table 1.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Protease inhibition in baseline genotype enzymes; means ± SDKi (nM) gt1b: 0.01 ± <0.01; gt1a: 0.01 ± 0.01; gt2a: 0.08 ± 0.02; gt2b: 0.15 ± 0.06; gt3a: 0.90 ± 0.2[1]
Reduced potency against two genotype 1b variants; means ± SDKi (nM) A156T: 5.3 ± 0.9; A156V: 12 ± 2[1]

Literature-Reported Treatment Conditions

Method
Biochemical protease inhibition with time-resolved fluorescence detection.
Co-treatment
None; reference inhibitors were tested separately.
Reported limits
The acquired main article does not specify Table 1 assay incubation time, concentration series, vehicle or replicate n. Referenced assay protocols were not retrieved; no conditions borrowed.
Methods and source locations

Compound reported in the paper: Grazoprevir; Compound label in the paper: MK-5172

Inhibition of the assayed NS3/4A proteases; no claim that all variants remain equally sensitive.

Results, In vitro activity and selectivity; Table 1 and footnote a; Materials and Methods, Compound and initial In vitro assays paragraph

Protease inhibition in baseline genotype enzymes; means ± SD: Time-resolved fluorescence protease assay; Table 1 values, not treatment concentrations. — Table 1, MK-5172 column, baseline genotype rows; footnote a

Reduced potency against two genotype 1b variants; means ± SD: Same comparative enzymatic panel; both unfavorable results retained. — Table 1, gt1b A156T and A156V rows; footnote a

Cell-based potency, serum shift and cytotoxicity

Cell-based study · Stable HCV replicon cell lines: gt1b con1 (HB1), gt1a and gt2a; Table 2 includes genotype 1b variant lines. [1]

Cell-based activity depended on genotype, serum condition and variant. The gt1b con1 EC50 increased in 40% normal human serum, and A156T was less sensitive. The cytotoxicity threshold exceeded the tested antiviral EC50 values.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Cell-based HCV RNA endpoint; means ± SDEC50 (nM) gt1b con1: 0.5 ± 0.1; gt1a: 2.0 ± 1; gt2a: 8.0 ± 4[1]
gt1b con1 potency in 40% normal human serum; mean ± SDEC50 (nM) 7.0 ± 3[1]
gt1b A156T cell-based potency; mean ± SDEC50 (nM) 131 ± 35[1]
Replicon-cell cytotoxicity; footnote identifies CC50 as mean onlyCC50 (nM) >50,000[1]

Literature-Reported Treatment Conditions

Method
Separate concentration-response assessments of RNA reduction and cell viability.
Co-treatment
MK-5172 alone.
Reported limits
Table 2 exposure duration, concentration series, replicate n and vehicle are not specified in the acquired main-text assay description. The gt1a line identifier is not given there. Referenced protocols were not retrieved.
Methods and source locations

Compound reported in the paper: Grazoprevir; Compound label in the paper: MK-5172

Cell-based assay endpoints only. EC50 and CC50 are assay outcomes, not recommended treatment doses.

Results, In vitro activity and selectivity; Table 2 and footnote a; Materials and Methods, initial In vitro assays paragraph

Cell-based HCV RNA endpoint; means ± SD: TaqMan-based replicon potency assay; routine serum condition described as 10% FBS. — Table 2 baseline genotype rows and footnote a; initial In vitro assays paragraph

gt1b con1 potency in 40% normal human serum; mean ± SD: Separate serum condition within the same Table 2 panel; not a clinical exposure target. — Table 2, gt1b con1 40% NHS row; footnote a

gt1b A156T cell-based potency; mean ± SD: Same stable-replicon panel; unfavorable variant result. — Table 2, gt1b A156T row; footnote a

Replicon-cell cytotoxicity; footnote identifies CC50 as mean only: MTS viability assay (Cell Titer Aqueous One); no SD supplied for CC50. — Table 2, CC50 row and footnote a; initial In vitro assays paragraph

Selective grazoprevir-dependent colocalization in engineered mammalian cells

Cell-based study · Engineered NIH3T3 (Flp-In-3T3) cells expressing NS3aH1-mCherry, plasma-membrane GNCR1-BFP-CAAX and mitochondrial Tom20-DNCR2-EGFP. [2]

Grazoprevir promoted NS3a colocalization with plasma-membrane GNCR1; danoprevir instead promoted mitochondrial DNCR2 colocalization. DMSO controls were included. The separate Figure 2b specificity experiment showed that grazoprevir did not recruit DNCR2 to mitochondrial NS3a.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
NS3a/reader colocalization at the plasma membrane versus mitochondriaQualitative imaging outcome Grazoprevir: GNCR1-associated plasma-membrane colocalization; danoprevir: DNCR2-associated mitochondrial colocalization.[2]
Negative specificity control for DNCR2-mediated mitochondrial recruitmentQualitative imaging outcome Grazoprevir did not promote the DNCR2/mitochondrial-NS3a colocalization observed with danoprevir.[2]

Literature-Reported Treatment Conditions

Treatment concentration
5 μM grazoprevir (Figure 2c); 10 μM grazoprevir (Figure 2b).
Exposure duration
15 minutes for the three-color Figure 2c experiment; 1 hour for Figure 2b.
Method
Drug treatment followed by fixation and confocal colocalization analysis.
Vehicle
Equal-volume DMSO controls; final DMSO percentage not specified in the read methods.
Co-treatment
Engineered NS3a/reader fusion proteins required; danoprevir and asunaprevir were separate comparator treatments.
Reported limits
Cell counts and P values are assigned to Supplementary Table 3, which was not retrieved. No exact correlation values or significance claims extracted.
Methods and source locations

Compound reported in the paper: Grazoprevir; Compound label in the paper: Grazoprevir

A research application as a chemical input in an engineered protein system; no endogenous trafficking or antiviral efficacy claim.

Results, Validation of PROCISiR in mammalian cells; Figure 2b–c and caption; Online Methods, Inhibitor sources and Confocal microscopy for fluorescent protein colocalization analysis

NS3a/reader colocalization at the plasma membrane versus mitochondria: Confocal microscopy and ImageJ Pearson correlation analysis; figure direction assessed visually without digitizing coefficients. — Figure 2c, schematic and colocalization distributions; Results S3; Online Methods S24

Negative specificity control for DNCR2-mediated mitochondrial recruitment: Figure 2b drug-specificity comparison with DMSO and asunaprevir controls. — Figure 2b and caption; Results S3; Online Methods S24

Grazoprevir In Vivo Studies

In diabetic mice carrying an engineered insulin translation switch, oral grazoprevir increased insulin output and lowered glucose relative to switch-bearing controls without drug. This was a combined gene-switch intervention. [3]

Oral triggering of an insulin gene switch in diabetic mice

Animal study · STZ-induced diabetic male C57BL/6 mice bearing plasmids for MCP-(NS3a)3, (GNCR)3-NSP3 and modified-insulin mRNA with an MCP-specific poly(A)-surrogate. [3]

Oral grazoprevir triggered modified-insulin output in the engineered system. Relative to gene-switch-bearing diabetic controls without drug, treated animals showed higher insulin, lower fasting glucose and improved glucose tolerance. Outcomes require the delivered gene switch.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Blood modified insulin and fasting glycemia at 20 hours after first administrationQualitative group comparison Higher modified insulin and lower fasting glycemia with grazoprevir; control insulin labeled BDL. n = 6 mice per group; mean ± SEM.[3]
Glucose tolerance at 24 hours after first administrationQualitative group comparison Glucose concentrations lower in the grazoprevir group over the displayed GTT time course; n = 6 mice per group; mean ± SEM.[3]

Conditions shared by the study groups

Route
Oral gavage.
Frequency
Caption wording: first of 3 daily administrations. The spacing of these administrations is not specified in the read text.
Treatment course
First administration 6 hours after plasmid delivery; insulin and fasting glycemia at 20 hours after first drug administration; GTT at 24 hours.
Vehicle
DMSO stock reported at 100 g/L for in vivo use; final dosing dilution/formulation not specified in the read text.
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Oral grazoprevir with insulin gene switch
3 mg/kg grazoprevir per administration.
Gene-switch-bearing diabetic mice without grazoprevir (Figure 3f minus group; Figure 3g Control).Higher circulating modified insulin, lower fasting glycemia and lower glucose during GTT than controls. Control insulin was below detection (BDL in Figure 3f).[3]
Oral grazoprevir with insulin gene switch
Model: Male C57BL/6 mice with STZ-induced insulin-deficient diabetes and plasmid-delivered insulin translation switch; n = 6 mice per group.
Reported limits: No exact numerical insulin/glucose values transcribed from plotted points. Final gavage formulation, dose-spacing details and randomization/blinding are not specified in the read locations.
Methods and source locations

Compound reported in the paper: Grazoprevir; Compound label in the paper: Grazoprevir

Animal validation of an engineered insulin-output system, not intrinsic antidiabetic efficacy of grazoprevir alone.

Results, Grazoprevir-triggered gene switch for disease treatments requiring on-demand drug activity; Figure 3f–g and caption; Materials and methods, Chemicals, Animal experiments, STZ T1D mouse model, Drug administration, Glycemia measurement and GTT

Blood modified insulin and fasting glycemia at 20 hours after first administration: Figure 3f viewed; insulin/glucose values were not estimated from plotted marks. — Figure 3f and caption

Glucose tolerance at 24 hours after first administration: Intraperitoneal glucose tolerance test; no curve-derived numeric values extracted. — Figure 3g and caption; Materials and methods, GTT

Oral grazoprevir with insulin gene switch · Results, Grazoprevir-triggered gene switch for disease treatments requiring on-demand drug activity; Figure 3f–g and caption; Materials and methods, Chemicals, Animal experiments, STZ T1D mouse model, Drug administration, Glycemia measurement and GTT

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 1350514-68-9
Applications Hepatitis C virus NS3/4a protease inhibitor
Formula C38H50N6O9S
Molecular Weight 766.9
Synonyms MK-5172
SMILES
COC1=CC2=C(N=C(CCCCC[C@@H]3C[C@H]3OC4=O)C(O[C@H]5CN(C([C@H](C(C)(C)C)N4)=O)[C@H](C(N[C@@]([C@@H]6C=C)(C6)C(NS(C7CC7)(=O)=O)=O)=O)C5)=N2)C=C1

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 93 mg/mL (121.26 mM)
Water Insoluble
Ethanol 93 mg/mL

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Grazoprevir Research References

  1. [1] Summa V, Ludmerer SW, McCauley JA, et al. MK-5172, a Selective Inhibitor of Hepatitis C Virus NS3/4a Protease with Broad Activity across Genotypes and Resistant Variants Antimicrobial Agents and Chemotherapy (2012). PMID: 22615282 DOI: 10.1128/AAC.00324-12 Source material
  2. [2] Foight Glenna Wink, Wang Zhizhi, Wei Cindy T., et al. Multi-input chemical control of protein dimerization for programming graded cellular responses Nature Biotechnology (2019). PMID: 31501561 DOI: 10.1038/s41587-019-0242-8 Source material
  3. [3] Shao Jiawei, Li Shichao, Qiu Xinyuan, et al. Engineered poly(A)-surrogates for translational regulation and therapeutic biocomputation in mammalian cells Cell Research (2024). PMID: 38172533 DOI: 10.1038/s41422-023-00896-y Source material

Publications

2 publications citing this product

  1. Deqiang Kong, .et al. , Nat Commun, 2024, Jun 8;15(1):4894 PMID: 38849338
  2. Xinyi Wang, .et al. , Nat Chem Biol, 2023, Oct 23 PMID: 37872400

Added to your cart

View Cart Checkout
Loading...